CVS Health (NYSE:CVS) had its target price upped by Leerink Swann from $82.00 to $90.00 in a research report sent to investors on Monday, January 8th, Marketbeat.com reports. They currently have an outperform rating on the pharmacy operator’s stock. Leerink Swann also issued estimates for CVS Health’s Q4 2017 earnings at $1.90 EPS, FY2017 earnings at $5.90 EPS, Q1 2018 earnings at $1.31 EPS, Q2 2018 earnings at $1.63 EPS and Q3 2018 earnings at $1.91 EPS.
A number of other equities research analysts have also issued reports on CVS. Needham & Company LLC reissued a hold rating on shares of CVS Health in a report on Sunday, September 10th. Oppenheimer reissued a buy rating and issued a $95.00 price objective on shares of CVS Health in a report on Monday, October 9th. Raymond James Financial raised shares of CVS Health from an outperform rating to a strong-buy rating and set a $90.00 price objective for the company in a report on Thursday, January 4th. They noted that the move was a valuation call. SunTrust Banks set a $85.00 target price on shares of CVS Health and gave the stock a buy rating in a research note on Thursday, October 12th. Finally, Citigroup set a $76.00 target price on shares of CVS Health and gave the stock a hold rating in a research note on Monday, December 4th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. CVS Health currently has a consensus rating of Buy and a consensus target price of $86.66.
CVS Health (NYSE:CVS) traded down $0.24 during trading hours on Monday, reaching $78.78. 7,096,589 shares of the company’s stock were exchanged, compared to its average volume of 9,051,855. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. The firm has a market capitalization of $79,800.00, a PE ratio of 16.28, a PEG ratio of 1.25 and a beta of 0.90. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.72.
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.54%. CVS Health’s dividend payout ratio (DPR) is presently 41.32%.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.61% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Westwood Holdings Group Inc. lifted its holdings in CVS Health by 7.1% in the first quarter. Westwood Holdings Group Inc. now owns 1,230,638 shares of the pharmacy operator’s stock valued at $96,605,000 after acquiring an additional 81,315 shares during the period. Cambria Investment Management L.P. raised its stake in shares of CVS Health by 1.2% during the 1st quarter. Cambria Investment Management L.P. now owns 17,548 shares of the pharmacy operator’s stock worth $1,378,000 after buying an additional 214 shares during the last quarter. Barings LLC raised its stake in shares of CVS Health by 39.6% during the 1st quarter. Barings LLC now owns 134,319 shares of the pharmacy operator’s stock worth $10,544,000 after buying an additional 38,092 shares during the last quarter. Tudor Investment Corp ET AL raised its stake in shares of CVS Health by 106.4% during the 1st quarter. Tudor Investment Corp ET AL now owns 59,741 shares of the pharmacy operator’s stock worth $4,690,000 after buying an additional 30,796 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of CVS Health by 1.1% during the 1st quarter. HighTower Advisors LLC now owns 221,664 shares of the pharmacy operator’s stock worth $17,405,000 after buying an additional 2,353 shares during the last quarter. Hedge funds and other institutional investors own 81.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://baseballnewssource.com/markets/leerink-swann-boosts-cvs-health-cvs-price-target-to-90-00/1817730.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.